[Risk of long-acting beta-2 agonists in asthma].
Orriols
Ramón
R
Servicio de Neumología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Vallano
Antonio
A
D000280:Administration, Inhalation; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019943:Amino Acid Substitution; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D000075202:Contraindications; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015201:Meta-Analysis as Topic; D017354:Point Mutation; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D018927:Anti-Asthmatic Agents; D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D018343:Receptors, Adrenergic, beta-2